Combination therapy with co-stimulatory factors
Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.
1. A method for treating an individual afflicted with rheumatoid arthritis, which comprises administering a therapeutically effective amount of an IL-1 inhibitor and an OX40 ligand inhibitor to the individual, wherein the IL-1 inhibitor comprises an IL-1ra polypeptide and the OX40 ligand inhibitor comprises an antibody that binds OX40 ligand.
2. The method of claim 1 , wherein the IL-1 inhibitor comprises an IL-1ra polypeptide fused to a human immunoglobulin constant region.
3. The method of claim 1 , wherein the IL-1 inhibitor comprises Fc IL-1ra.
4. The method of claim 1 , wherein the IL-1 inhibitor comprises the amino acid sequence of SEQ ID NO 3.
5. The method of claim 1 , wherein the IL-1 inhibitor comprises anakinra.
6. The method of claim 1 , wherein the administering is discontinued for at least one day and then resumed.
7. The method of claim 6 , wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.
8. The method of claim 2 , wherein the administering is discontinued for at least one day and then resumed.
9. The method of claim 8 , wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.
10. The method of claim 3 , wherein the administering is discontinued for at least one day and then resumed.
11. The method of claim 10 , wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.
12. The method of claim 4 , wherein the administering is discontinued for at least one day and then resumed.
13. The method of claim 12 , wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.
14. The method of claim 5 , wherein the administering is discontinued for at least one day and then resumed.
15. The method of claim 14 , wherein the administering is resumed to treat a recurrence of the rheumatoid arthritis.